Core D: Neuroimaging Core

神经影像核心摘要 由Adam Brickman博士和Brad Christian博士领导的ABC-DS神经成像核心将应用最先进的技术 正电子发射断层扫描(PET)和磁共振成像(MRI)神经成像技术 唐氏综合征(DS)患者淀粉样蛋白、tau蛋白和神经退行性变(AT(N))的定量 阿尔茨海默病(AD)的病理生理模型及其相关脑血管，微结构， 和功能性生物标记物。神经成像核心的具体目标是：(1)监督协调 获取8个临床表现部位的PET和MRI数据；(2)量化主要结果 每种神经成像模式的测量；(3)将处理后的神经成像数据集成到ABC-DS中 支持拟议项目的数据库；和(4)提供经过管理的主要成果变量和原始数据 将神经成像数据提供给更广泛的科学界。整体扫描方案将遵循已开发的方案 由阿尔茨海默病神经成像倡议(ADNI)为MRI(结构和功能)和PET(淀粉样蛋白， Tau，FDG)。结果变量由特定于医疗模式的分析节点导出，并对每种医疗模式进行分析 由一个在神经成像生物标记物方面拥有专业知识的实验室。核心将利用NIA赞助的 目前支持正在进行的大规模AD神经成像计划的资源(例如ADNI、Dominly 遗传性阿尔茨海默病网络(DIAN))，以提供完全开发的数据访问管道，鼓励科学 DS神经影像生物标志物的研究。

Neuroimaging Core Abstract The ABC-DS Neuroimaging Core, led by Drs. Adam Brickman and Brad Christian, will apply state-of-the art positron emission tomography (PET) and magnetic resonance imaging (MRI) neuroimaging techniques to quantitate amyloid, tau, and neurodegeneration (AT(N)) in Down syndrome (DS) according to current pathophysiological models of Alzheimer’s disease (AD) together with related cerebrovascular, microstructural, and functional biomarkers. The specific aims of the Neuroimaging Core are to: (1) oversee the harmonized acquisition of PET and MRI data at each of the 8 clinical performance sites; (2) quantitate primary outcome measures for each neuroimaging modality; (3) integrate the processed neuroimaging data into a ABC-DS database to support the proposed projects; and (4) provide curated primary outcome variables and raw neuroimaging data to the wider scientific community. The overall scanning protocols will follow those developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for MRI (structural and functional) and PET (amyloid, tau, FDG). The outcome variables are derived by modality-specific analytic nodes, with each modality analyzed by a single laboratory with expertise in that neuroimaging biomarker. The Core will utilize NIA-sponsored resources that currently support ongoing large-scale AD neuroimaging initiatives (e.g. ADNI, Dominantly Inherited Alzheimer Network (DIAN)) to provide a fully developed data-access pipeline that encourages scientific investigation of neuroimaging biomarkers in DS.